Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled,…
- K. Gadde, D. Allison, W. Day
- MedicineThe Lancet
- 16 April 2011
Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.
- J. Davidson, E. Foa, K. Gadde
- Psychology, MedicineArchives of General Psychiatry
- 1 October 2004
All active treatments were superior to PBO on primary outcomes and combined treatment did not yield any further advantage, notwithstanding the benefits of treatment.
Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- D. Allison, K. Gadde, W. Day
- MedicineObesity
- 3 November 2011
PHEN/TPM CR demonstrated dose‐dependent effects on weight and metabolic variables in the direction expected to be beneficial with no evidence of serious adverse events induced by treatment.
Serotonin-Related Gene Polymorphisms and Central Nervous System Serotonin Function*
- Redford B Williams, D. Marchuk, I. Siegler
- Psychology, BiologyNeuropsychopharmacology
- 1 March 2003
Findings suggest that effects of serotonin-related gene polymorphisms on CNS serotonergic function vary as a function of both ethnicity and gender, as well as the broad range of biological and behavioral functions that are regulated by CNSSerotonin function.
Rational Design of a Combination Medication for the Treatment of Obesity
- F. Greenway, M. J. Whitehouse, M. Cowley
- Biology, MedicineObesity
- 1 January 2009
Results supported the hypothesis that NAL, through blockade of β‐endorphin mediated POMC autoinhibition, prevents the classic weight loss plateau observed with monotherapies such as BUP.
Zonisamide for weight loss in obese adults: a randomized controlled trial.
- K. Gadde, Deborah M. Franciscy, H. Wagner, K. Krishnan
- MedicineJAMA
- 9 April 2003
Zonisamide treatment over the 16-week study duration was associated with significantly greater weight loss than was placebo, and zonisamide and hypocaloric diet resulted in more weight loss in the treatment of obesity in this short-term, preliminary trial.
Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial.
- J. Davidson, K. Gadde, R. Weisler
- Medicine, PsychologyJAMA
- 10 April 2002
This study fails to support the efficacy of H perforatum in moderately severe major depression; the result may be due to low assay sensitivity of the trial, but the complete absence of trends suggestive of efficacy is noteworthy.
The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.
- K. Connor, V. Payne, K. Gadde, Wei Zhang, J. Davidson
- Psychology, MedicineJournal of Clinical Psychiatry
- 15 January 2005
Although from a small, open-label study, these results suggest that aripiprazole holds promise for treating OCD, and larger, controlled studies of aripIPrazole as monotherapy and as augmentation in partial responders to selective serotonin reuptake inhibitors are needed.
Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.
- James W. Anderson, F. Greenway, K. Fujioka, K. Gadde, J. Mckenney, P. O'Neil
- MedicineObesity Research
- 1 July 2002
Bupropion SR 300 and 400 mg/d were well-tolerated by obese adults and were associated with a 24-week weight loss of 7.2% and 10.1% and sustained weight losses at 48 weeks.
Obesity: Pathophysiology and Management.
- K. Gadde, Corby K. Martin, H. Berthoud, S. Heymsfield
- MedicineJournal of the American College of Cardiology
- 2 January 2018
...
...